Viatris Korea expands cardiovascular portfolio through Vascepa deal with Alvogen

Coverage, in order

1. 2d ago
   Korea Biomedical Review South Korea obscure

   Viatris Korea expands cardiovascular portfolio through Vascepa deal with Alvogen

   Viatris Korea is expanding its cardiovascular drug portfolio through an exclusive distribution and co-promotion agreement with Alvogen Korea for Vascepa (icosapent ethyl), a treatment designed to reduce residual cardiovascular risk in certain high-risk patients already receiving statin therapy.Alvog

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.